6 of the world's most venomous snakes that could easily kill you
Venomous or not, snakes are one of the most feared creatures on Earth. These cold-blooded, limbless reptiles slither, hiss and even bite their prey. Venomous snakes possess venom that contains toxic substances. They inject venom into prey by using their fangs which can cause paralysis, internal bleeding, organ failure, cardiac arrest and even death.
Approximately 5.4 million individuals are bitten by venomous snakes annually, leading to an estimated 81,000 to 138,000 fatalities, as reported by the World Health Organization (WHO). However, snakes only bite in self-defense-they are more scared of us than we are of them. Dion Wedd, curator of the Territory Wildlife Park, NT, said to Australia Geographic that snakes do not view humans as potential meals, nor do they bite aggressively out of spite. They use their venom to immobilise prey that would be too difficult for them to consume otherwise. Yet, they have the second-largest number of human fatalities attributed to any animal.
Only few venomous snakes can kill a human if left untreated. Since the development of anti-venom, the fatalities due to snake bites have reduced. But the problem of snake bites still persists, especially in developing countries where anti-venom is less easily available. Here are 6 venomous snakes in the world that are deadly enough to kill a human:
Inland taipan
According to the International Journal of Neuropharmacology, Inland Taipan is the most venomous snake in the world, as noted by Live Science. This means that only a tiny bit of this snake's venom is fatal enough to kill humans.
As per BBC Wildlife, one bite contains enough lethality to kill atleast 100 adult humans. They are mostly found in Queensland, Centre East and South Australia in pre dug borrows of other animals. Due to its hiding nature, they barely come in contact with humans, thankfully.
As per Live Science, the main ingredient of Inland Taipan's venom is hyaluronidase enzyme. This enzyme increases the speed at which toxins are absorbed in the victim's body.
Coastal taipan
Found mostly in the wet forests of temperate and tropical coastal regions, coastal taipan is a highly venomous snake. Parts Australia like Queensland, New South Wales is home to this subspecies. According to the Australian Museum, its incredible speed makes it difficult to be spared of its bites. As per Australian Geographic, before an effective anti venom was produced, its bite was always fatal.
Black mamba
Known for its black mouth, Black Mambas are highly aggressive species of snake. Found in sub Saharan Africa, they are the most feared of all. Like most snakes, even Mambas do not seek out humans but if they are threatened, they will attack.
According to the BBC, if you are bitten by a black mamba, symptoms such as slurred speech and muscle twitches will follow in 10 minutes and likely death in half an hour.
Russel's viper
Russel Vipers' bite is the most painful of all. They are quite aggressive and one of the 'the Big Four' along with Indian Cobra, common krait and saw-scaled viper. As per the BBC, these snakes account for 43% of all snakebites in India.
However, an anti venom has been developed against its venom saving many lives.
Indian cobra
Cobras are the world's longest venomous snake. (Source-Freepik)
According to the Natural History Museum, King Cobra is the world's longest venomous snake in the world. Did you know if a cobra is threatened they can lift themselves off the ground about a third of their body length.
They are one of the deadliest snakes and found in India. Their encounters with Humans are quite frequent in India especially in rural areas during monsoon season. Sean Carroll, a molecular biologist wrote in the New York Times that a single bite can kill a human in 15 minutes and an adult elephant in just a few hours.
Saw-scaled viper
Part of the Big Four, saw scaled vipers are found in the Middle East, South Asia and Central Asia. They are typically aggressive and can be identified by the 'sizzling' sound they make when threatened.
As per BBC Wildlife, they are responsible for an estimated 5,000 human fatalities per year in India alone.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
NDTV
5 hours ago
- NDTV
WHO Is Finalising A New Treaty To Prep For The Next Pandemic, But US Isn't Signing
On March 20, 2025, members of the World Health Organization adopted the world's first pandemic agreement, following three years of 'intensive negotiations launched by governments in response to the devastating impacts of the COVID-19 pandemic.' The U.S., however, did not participate, in part because of its intention to withdraw from the WHO. Global health experts are hailing the agreement as a historic moment. What does the agreement mean for the world, and how can it make everyone safer and more prepared for the next pandemic? The Conversation asked Nicole Hassoun, a professor at Binghamton University and executive director of Global Health Impact, to explain the pandemic accord, its prospects for advancing global health, and the significance of the U.S.'s absence from it. What will the pandemic agreement do? The accord will bolster pandemic preparation within individual countries and around the world. Countries signing onto the agreement are committing to improve their disease surveillance and grow their heath care workforces, strengthen their regulatory systems and invest in research and development. It encourages countries to strengthen their health regulations and infrastructure, improve communication with the public about pandemics and increase funding for preparation and response efforts. It also includes new mechanisms for producing and distributing vaccines and other essential countermeasures. Finally, it encourages countries to coordinate their responses and share information about infectious diseases and intellectual property so that vaccines and other essential countermeasures can be made available more quickly. The agreement will take effect once enough countries ratify it, which may take several years. Why isn't the US involved? The Biden administration was broadly supportive of a pandemic agreement and was an active participant in negotiations. Prior to Donald Trump's reelection, however, Republican governors had signed a letter opposing the treaty, echoing a conservative think tank's concerns about U.S. sovereignty. The U.S. withdrew from negotiations when President Trump signed an executive order to withdraw from the WHO on the day he was inaugurated for his second term. Why could the lack of US involvement be beneficial for the world? The lack of U.S. involvement likely resulted in a much more equitable treaty, and it is not clear that countries could have reached an agreement had the U.S. continued to object to key provisions. It was only once the U.S. withdrew from the negotiations that an agreement was reached. The U.S. and several other wealthy countries were concerned with protecting their pharmaceutical industry's profits and resisted efforts aimed at convincing pharmaceutical companies to share the knowledge, data and intellectual property needed for producing new vaccines and other essential countermeasures. Other negotiators sought greater access to vaccines and other treatments during a pandemic for poorer countries, which often rely on patented technologies from global pharmaceutical companies. While most people in wealthy countries had access to COVID-19 vaccines as early as 2021, many people in developing countries had to wait years for vaccines. How could the agreement broaden access for treatments? One of the contentious issues in the pandemic agreement has to do with how many vaccines manufacturers in each country must share in exchange for access to genetic sequences to emerging infectious diseases. Countries are still negotiating a system for sharing the genetic information on pathogens in return for access to vaccines themselves. It is important that researchers can get these sequences to make vaccines. And, of course, people need access to the vaccines once they are developed. Still, there are many more promising aspects of the agreement for which no further negotiations are necessary. For instance, the agreement will increase global vaccine supply by increasing manufacturing around the world. The agreement also specifies that countries and the WHO should work together to create a mechanism for fairly sharing the intellectual property, data and knowledge needed to produce vaccines and other essential health products. If financing for new innovation requires equitable access to the new technologies that are developed, many people in poor countries may get access to vaccines much more quickly in the next pandemic. The agreement also encourages individual countries to offer sufficient incentives for pharmaceutical companies to extend access to developing countries. If countries implement these changes, that will benefit people in rich countries as well as poor ones. A more equitable distribution of vaccines can contain the spread of disease, saving millions of lives. What more should be done, and does the US have a role to play? In my view, the best way to protect public health moving forward is for countries to sign on to the agreement and devote more resources to global health initiatives. This is particularly important given declining investment and participation in the WHO and the contraction of other international health initiatives, such as USAID. Without international coordination, it will become harder to catch and address problems early enough to prevent epidemics from becoming pandemics. It will also be imperative for member countries to provide funding to support the agreement's goals and secure the innovation and access to new technologies. This requires building the basic health infrastructure to ensure shots can get into people's arms.
The Hindu
7 hours ago
- The Hindu
Europe suffers its largest diphtheria outbreak in 70 years
The largest diphtheria outbreak to strike Western Europe in 70 years has been affecting vulnerable people such as migrants and the homeless since 2022, new research said Wednesday. Diphtheria is a highly contagious bacterial infection that can attack the respiratory tract and spread throughout the body, causing a sore throat, fever and other symptoms. For unvaccinated people, it can be fatal in around 30 percent of cases, and is deadlier for children, according to the World Health Organization. In 2022, there was an unusual surge in the bacteria that causes diphtheria -- Corynebacterium diphtheriae -- in several European countries, particularly among recently arrived migrants, according to a study in the New England Journal of Medicine. That year 362 cases were recorded by the European Centre for Disease Prevention and Control. Contact tracing and screening helped tamp down the outbreak, but rare infections have continued to be recorded, the researchers said. A total of 536 cases, including three deaths, have been recorded across Europe since the start of 2022. Patient samples from 10 countries showed that 98 percent of the cases were in males with an average age of 18. Almost all had recently migrated. "The outbreak, which mainly affected migrants from Afghanistan and Syria, was not the result of people being infected in their countries of origin, but during their migration journeys or in their places of accommodation in European countries," said a joint statement from France's public health agency and the Pasteur Institute. The genetic similarities between the strains seen in people from different countries suggests that there was a "recent point of contact, outside the country of origin" at the source of the outbreak, the statement added. The exact areas affected by the outbreak remains unclear. But a genetic link between the 2022 strain and the one detected in Germany this year indicates that "the bacteria continues to circulate quietly in Western Europe," the statement said. Vaccination is very effective at fending off diphtheria, and the researchers emphasised the importance of immunisation programmes for the general public. They also called for European nations to do more to ensure their most vulnerable people avoid contracting the disease. That included raising awareness of the symptoms among doctors and those in contact with migrants and the homeless, as well as increasing access to vaccines and antibiotic drugs.
Hans India
8 hours ago
- Hans India
AB-PMJAY, Jan Aushadhi Kendras boosting healthcare for middle class in last 11 years
New Delhi: Flagship scheme like the Ayushman Bharat-Pradhan Mantri Jan Arogya Yojana (AB-PMJAY) and the Jan Aushadhi Kendras under the Pradhan Mantri Bhartiya Janaushadhi Pariyojana (PMBJP) has significantly enhanced healthcare for middle class in the last 11 years, according to an official statement issued on Thursday. 'Healthcare in India has seen a quiet but far-reaching shift in the last eleven years. Through a blend of targeted public schemes and digital reach, the Government has made quality healthcare both affordable and accessible for millions, especially the middle class,' the statement said. With more than 41.02 crore Ayushman Cards created in 33 States and Union Territories, as of May 30, AB-PMJAY has emerged as one of the world's largest publicly funded health assurance schemes. The scheme has enabled 8.59 crore hospital admissions worth Rs 1,19,858 crore, ensuring access to secondary and tertiary care without pushing families into debt, the statement said. Further, with the number of Jan Aushadhi Kendras rising to 16,469, as of May 30, from just 80 in 2014, the PMBJP brought essential medicines within reach of the common citizen. These outlets offer medicines that cost 50 to 80 per cent less than branded options, with strict quality standards ensured through WHO-GMP certified suppliers. The scheme serves around 10 to 12 lakh people daily, and cumulative savings over the last eleven years are estimated to be more than Rs 38,000 crore, the statement said. The product range now includes 2,110 medicines, including for chronic conditions like diabetes or heart disease, and 315 surgical products, covering all major treatments, cutting down financial stress for millions of families, especially the middle class. 'From free hospitalisation for senior citizens to low-cost medicines available nationwide, people today have better control over their health expenses. The digital backbone supporting these schemes has made enrolment, access, and tracking easier than ever. This change has allowed the middle class to benefit from savings on medicines, timely treatment, and greater medical security without bureaucratic hassles,' the statement said. 'Over the past eleven years, the government has shown unwavering commitment to uplifting the middle class in meaningful ways. The policies and reforms introduced have not only eased everyday challenges but also strengthened financial security, housing, healthcare, and skill development,' it added.
